Evidence map›Paper›PMID 27007115›Full record

ArticlePloS one2016

Ionomycin Treatment Renders NK Cells Hyporesponsive.

Gema Romera-Cárdenas, L Michael Thomas, Sheila Lopez-Cobo, Eva M García-Cuesta, Eric O Long, Hugh T Reyburn

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. NK Cell Hyporesponsiveness: More Is Not Always Better.International journal of molecular sciences · 2019
    Review
  12. Article
  13. Article
  14. Effect of Natural Compounds on NK Cell Activation.Journal of immunology research · 2018
    Review
  15. Frontiers in immunology · 2018
    Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Gema Romera-CárdenasCentro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas, CNB-CSIC, Madrid, Spain.
L Michael ThomasLaboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, United States of America.
Sheila Lopez-CoboCentro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas, CNB-CSIC, Madrid, Spain.
Eva M García-CuestaCentro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas, CNB-CSIC, Madrid, Spain.
Eric O LongLaboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, United States of America.
Hugh T ReyburnCentro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas, CNB-CSIC, Madrid, Spain.
Centro Nacional de Biotecnología · ESNational Institute of Allergy and Infectious Diseases · USConsejo Superior de Investigaciones Científicas · ES

Funding

Regulation of innate lymphocyte functionZIAAI000525 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI LONG, ERIC O · 2009 to 2024
$12.0M
Intramural NIH HHS
6 · The paper itself

Abstract

Natural killer cells are cytotoxic lymphocytes important in immune responses to cancer and multiple pathogens. However, chronic activation of NK cells can induce a hyporesponsive state. The molecular basis of the mechanisms underlying the generation and maintenance of this hyporesponsive condition are unknown, thus an easy and reproducible mechanism able to induce hyporesponsiveness on human NK cells would be very useful to gain understanding of this process. Human NK cells treated with ionomycin lose their ability to degranulate and secrete IFN-γ in response to a variety of stimuli, but IL-2 stimulation can compensate these defects. Apart from reductions in the expression of CD11a/CD18, no great changes were observed in the activating and inhibitory receptors expressed by these NK cells, however their transcriptional signature is different to that described for other hyporesponsive lymphocytes.

Indexed as

Cell DegranulationCell LineFlow CytometryHumansInterferon-gammaInterleukin-2IonomycinKiller Cells, NaturalTranscription, GeneticInterferon-gammaInterleukin-2Ionomycin

Identifiers

PMID27007115
PMCPMC4805247
OpenAlexW2304688609

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.